Patents by Inventor Masami Yamada

Masami Yamada has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • NITROGEN-CONTAINING HETEROCYCLIC COMPOUND
    Publication number: 20240109874
    Abstract: The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity and useful as an agent for the prophylaxis or treatment of Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies, and the like. The present invention relates to a compound represented by the formula (I) or a salt thereof. wherein each symbol is as described in the specification, or a salt thereof.
    Type: Application
    Filed: November 8, 2023
    Publication date: April 4, 2024
    Inventors: Masami YAMADA, Shinkichi SUZUKI, Takahiro SUGIMOTO, Minoru NAKAMURA, Hiroki SAKAMOTO, Makoto KAMATA
  • VEHICLE CONTROL APPARATUS
    Publication number: 20240092337
    Abstract: A vehicle control apparatus includes front-wheel and rear-wheel driving systems, and a control system. The front-wheel driving system includes a first travel motor mechanically coupled to a front wheel of a vehicle and a first accumulator electrically coupled to the first travel motor. The rear-wheel driving system includes a second travel motor mechanically coupled to a rear wheel of the vehicle and a second accumulator electrically coupled to the second travel motor. The control system includes one or more processors and one or more memories communicably coupled to the one or more processors, and controls the first and second travel motors. When a difference between an SOC of the first accumulator and an SOC of the second accumulator is greater than a threshold value, the one or more processors change a torque distribution ratio between the first and second travel motors from a reference distribution ratio.
    Type: Application
    Filed: September 13, 2023
    Publication date: March 21, 2024
    Inventors: Hiroshi KUSANO, Yoshinobu YAMAZAKI, Masami OGURI, Akihiro NABESHIMA, Yoshiyuki JIN, Takeshi YONEDA, Fumiya SATO, Keigo YAMADA, Takumi ARAKI, Shuntaro MIURA
  • NOVEL AMINO ACID DERIVATIVES
    Publication number: 20230312479
    Abstract: A novel amino acid derivative is provided, wherein the amino acid derivative is expected to improve binding affinity of polypeptides comprising the derivative therein.
    Type: Application
    Filed: March 28, 2023
    Publication date: October 5, 2023
    Inventors: Haruaki Kurasaki, Masatoshi Matsumoto, Ayumu Matsuda, Yutaka Kobayashi, Masahiko Kinebuchi, Tomoko Ashizawa, Katsuma Matsui, Motoki Murai, Masami Yamada
  • NOVEL AMINO ACID DERIVATIVES
    Publication number: 20230257343
    Abstract: A novel amino acid derivative is provided, wherein the amino acid derivative is expected to improve solubility of polypeptides comprising the derivative therein.
    Type: Application
    Filed: February 14, 2023
    Publication date: August 17, 2023
    Inventors: Naoki OKADA, Kyosuke UEDA, Masatoshi TAKUWA, Shunichi NAKANO, Kotaro TOKUMOTO, Tomoko ASHIZAWA, Shuhei YAMAKOSHI, Yutaka KOBAYASHI, Katsuma MATSUI, Ayumu MATSUDA, Masatoshi MATSUMOTO, Keiichi MASUYA, Atsushi YOSHIZAWA, Masahiko KINEBUCHI, Takeru EHARA, Masami YAMADA, Kouki MORIMOTO, Yoshihide MIZUKOSHI, Haruaki KURASAKI, Motoki MURAI, Kentarou FUKUMOTO, Douglas Robert CARY
  • NITROGEN-CONTAINING HETEROCYCLIC COMPOUND
    Publication number: 20220411413
    Abstract: The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity and useful as an agent for the prophylaxis or treatment of Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies, and the like. The present invention relates to a compound represented by the formula (I) or a salt thereof. wherein each symbol is as described in the specification, or a salt thereof.
    Type: Application
    Filed: July 25, 2022
    Publication date: December 29, 2022
    Inventors: Masami YAMADA, Shinkichi SUZUKI, Takahiro SUGIMOTO, Minoru NAKAMURA, Hiroki SAKAMOTO, Makoto KAMATA
  • Substituted pyrido[1,2-a]pyrimidines and pyrazino[1,2-a]pyrimidines for enhancing AMPA receptor function
    Patent number: 11407748
    Abstract: The present invention aims to provide a heterocyclic compound having an AMPA receptor potentiator effect, which is expected to be useful as an agent for the prophylaxis or treatment of depression, Alzheimer's disease, schizophrenia, attention deficit hyperactivity disorder (ADHD) and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof.
    Type: Grant
    Filed: October 4, 2018
    Date of Patent: August 9, 2022
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Shinji Nakamura, Satoshi Mikami, Tomoaki Hasui, Tohru Yamashita, Shinji Morimoto, Hidekazu Tokuhara, Norio Oyabu, Masami Yamada, Atsuko Ochida, Kazuaki Takami, Xin Liu
  • Heterocyclic compound
    Patent number: 11236099
    Abstract: The present invention aims to provide a compound that may be useful for the prophylaxis or treatment of constipation and the like. The present invention provides a compound represented by the following formula (I): wherein each symbol is as described in the specification, or a salt thereof.
    Type: Grant
    Filed: June 19, 2018
    Date of Patent: February 1, 2022
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Kazuaki Takami, Masaki Seto, Shinobu Sasaki, Haruhi Ando, Masaki Ogino, Tomoko Ohashi, Toshihiro Imaeda, Ikuo Fujimori, Yasuhiro Tsukimi, Masami Yamada, Kenichiro Shimokawa, Takeshi Wakabayashi, Masataka Murakami, Makoto Fushimi, Tomohiro Okawa, Jinichi Yonemori, Tomohiro Ohashi, Hideo Suzuki, Hironobu Maezaki, Ayumu Sato, Yasutomi Asano, Steve Swann
  • HETEROCYCLIC COMPOUND
    Publication number: 20220017530
    Abstract: The present invention aims to provide a compound that may be useful for the prophylaxis or treatment of constipation and the like. The present invention provides a compound represented by the following formula (I): wherein each symbol is as described in the specification, or a salt thereof.
    Type: Application
    Filed: September 15, 2021
    Publication date: January 20, 2022
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Kazuaki Takami, Masaki Seto, Shinobu Sasaki, Haruhi Ando, Masaki Ogino, Tomoko Ohashi, Toshihiro Imaeda, Ikuo Fujimori, Yasuhiro Tsukimi, Masami Yamada, Kenichiro Shimokawa, Takeshi Wakabayashi, Masataka Murakami, Makoto Fushimi, Tomohiro Okawa, Jinichi Yonemori, Tomohiro Ohashi, Hideo Suzuki, Hironobu Maezaki, Ayumu Sato, Yasutomi Asano, Steve Swann
  • HETEROCYCLIC COMPOUND
    Publication number: 20210139491
    Abstract: The present invention aims to provide a compound that may be useful for the prophylaxis or treatment of constipation and the like. The present invention provides a compound represented by the following formula (I): wherein each symbol is as described in the specification, or a salt thereof.
    Type: Application
    Filed: June 19, 2018
    Publication date: May 13, 2021
    Inventors: Kazuaki TAKAMI, Masaki SETO, Shinobu SASAKI, Haruhi ANDO, Masaki OGINO, Tomoko OHASHI, Toshihiro IMAEDA, Ikuo FUJIMORI, Yasuhiro TSUKIMI, Masami YAMADA, Kenichiro SHIMOKAWA, Takeshi WAKABAYASHI, Masataka MURAKAMI, Makoto FUSHIMI, Tomohiro OKAWA, Jinichi YONEMORI, Tomohiro OHASHI, Hideo SUZUKI, Hironobu MAEZAKI, Ayumu SATO, Yasutomi ASANO, Steve SWANN
  • 2,3-dihydro-4H-1,3-benzoxazin-4-one derivatives as modulators of cholinergic muscarinic M1 receptor
    Patent number: 10899752
    Abstract: The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity, which may be useful as a prophylactic or therapeutic drug for Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies and the like. The present invention relates to a compound represented by the formula (I) or a salt thereof: wherein each symbol is as defined in the attached DESCRIPTION.
    Type: Grant
    Filed: April 25, 2019
    Date of Patent: January 26, 2021
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Takahiro Sugimoto, Shinkichi Suzuki, Hiroki Sakamoto, Masami Yamada, Minoru Nakamura, Makoto Kamata, Kenichiro Shimokawa, Masataka Murakami, Jinichi Yonemori, Takuto Kojima
  • NITROGEN-CONTAINING HETEROCYCLIC COMPOUND
    Publication number: 20210009572
    Abstract: The present invention provides a compound having a cholinergic muscarinic Ml receptor positive allosteric modulator activity and useful as an agent for the prophylaxis or treatment of Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies, and the like. The present invention relates to a compound represented by the formula (I) or a salt thereof. wherein each symbol is as described in the specification, or a salt thereof.
    Type: Application
    Filed: September 30, 2020
    Publication date: January 14, 2021
    Inventors: Masami YAMADA, Shinkichi SUZUKI, Takahiro SUGIMOTO, Minoru NAKAMURA, Hiroki SAKAMOTO, Makoto KAMATA
  • Nitrogen-containing heterocyclic compound
    Patent number: 10865200
    Abstract: The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity and useful as an agent for the prophylaxis or treatment of Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies, and the like. The present invention relates to a compound represented by the formula (I) or a salt thereof. wherein each symbol is as described in the specification, or a salt thereof.
    Type: Grant
    Filed: December 4, 2018
    Date of Patent: December 15, 2020
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Masami Yamada, Shinkichi Suzuki, Takahiro Sugimoto, Minoru Nakamura, Hiroki Sakamoto, Makoto Kamata
  • HETEROCYCLIC COMPOUND
    Publication number: 20200270243
    Abstract: The present invention aims to provide a heterocyclic compound having an AMPA receptor potentiator effect, which is expected to be useful as an agent for the prophylaxis or treatment of depression, Alzheimer's disease, schizophrenia, attention deficit hyperactivity disorder (ADHD) and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof.
    Type: Application
    Filed: October 4, 2018
    Publication date: August 27, 2020
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Shinji NAKAMURA, Satoshi MIKAMI, Tomoaki HASUI, Tohru YAMASHITA, Shinji MORIMOTO, Hidekazu TOKUHARA, Norio OYABU, Masami YAMADA, Atsuko OCHIDA, Kazuaki TAKAMI, Xin LIU
  • Management server, connection support method, and non-transitory computer-readable recording medium encoded with connection support program
    Patent number: 10715489
    Abstract: A management server disposed outside a firewall and supporting connection of communications between a control target device disposed inside the firewall and a cloud server disposed outside the firewall, includes a server-side session establishing portion to, based on a request from a relay device disposed inside the firewall, establish a session with the relay device, a device information acquiring portion to acquire device information about the control target device from the relay device via the established session, and an update determining portion to, in response to reception of a request of connecting to the control target device from the cloud server, determine whether to update the device information.
    Type: Grant
    Filed: February 5, 2015
    Date of Patent: July 14, 2020
    Assignee: KONICA MINOLTA, INC.
    Inventors: Hisashi Uchida, Kazumi Sawayanagi, Noriaki Asamoto, Masami Yamada, Shuji Yoneda, Kazuya Anezaki, Akihiro Torigoshi, Yasutaka Ito
  • Information processing system controlling performance of virus detection processing at devices included in the system, and information processing apparatus and recording medium
    Patent number: 10657256
    Abstract: One information processing apparatus among a plurality of information processing apparatuses performs virus detection processing for detecting a computer virus. When a computer virus has been detected from the one information processing apparatus by the virus detection processing, the one information processing apparatus transmits an execution request to perform the virus detection processing to another information processing apparatus different from the one information processing apparatus among the plurality of information processing apparatuses.
    Type: Grant
    Filed: October 10, 2017
    Date of Patent: May 19, 2020
    Assignee: KONICA MINOLTA, INC.
    Inventors: Katsuhiko Akita, Yuji Okamoto, Kazumi Sawayanagi, Masami Yamada, Atsushi Tamura, Yasutaka Ito, Yoshikazu Ikenoue
  • Aromatic ring compound
    Patent number: 10548877
    Abstract: Provided is a compound having a cholinergic muscarine M1 receptor positive allosteric modulator activity. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof has a cholinergic muscarine M1 receptor positive allosteric modulator activity, and is useful as a prophylactic or therapeutic drug for Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies and the like.
    Type: Grant
    Filed: March 9, 2017
    Date of Patent: February 4, 2020
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Masaki Ogino, Eiji Kimura, Shinkichi Suzuki, Kouji Fuji, Tomohiro Ohashi, Makoto Fushimi, Kei Masuda, Tatsuki Koike, Takeshi Wakabayashi, Jinichi Yonemori, Masami Yamada
  • Quinazolinone and benzotriazinone compounds with cholinergic muscarinin M1 receptor positive allosteric modulator activity
    Patent number: 10548899
    Abstract: The present invention provides a compound which has a cholinergic muscarinic M1 receptor positive allosteric modulator activity and may be useful as a medicament such as an agent for the prophylaxis or treatment of Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, Lewy body dementia and the like. The present invention relates to a compound represented by the formula (I) or a salt thereof. In the formula (I), each symbol is as described in the attached specification.
    Type: Grant
    Filed: October 19, 2016
    Date of Patent: February 4, 2020
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Takahiro Sugimoto, Shinkichi Suzuki, Hiroki Sakamoto, Masami Yamada, Minoru Nakamura, Makoto Kamata, Kenichiro Shimokawa, Masaki Ogino, Eiji Kimura, Masataka Murakami, Takuto Kojima, Jinichi Yonemori
  • Multifunction device, reboot method, and non-transitory recording medium storing computer readable program
    Patent number: 10484571
    Abstract: A multifunction device integrally includes a first device and a second device. The first device has a first system, and the second system has a second system. The second device requests, in response to a predetermined command entered, a first snapshot of the first device from the first device. The first device generates the first snapshot in response to a request from the second device, and sends the first snapshot to the second device. The second device generates a second snapshot of the second device in response to the predetermined command entered, and saves, to a save destination, the first snapshot sent and the second snapshot. The first device starts the first system by using the first snapshot saved in the save destination. The second device starts the second system by using the second snapshot saved in the save destination.
    Type: Grant
    Filed: August 9, 2018
    Date of Patent: November 19, 2019
    Assignee: Konica Minolta, Inc.
    Inventors: Masami Yamada, Yuji Okamoto, Katsuhiko Akita, Kazumi Sawayanagi, Yasutaka Ito, Atsushi Tamura
  • Isoindoline-1-one derivatives as cholinergic muscarinic M1 receptor positive alloesteric modulator activity for the treatment of Alzheimers disease
    Patent number: 10457670
    Abstract: The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity and useful as an agent for the prophylaxis or treatment of Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies, and the like. The present invention relates to a compound represented by the formula (I) or a salt thereof. wherein each symbol is as described in the specification, or a salt thereof.
    Type: Grant
    Filed: December 4, 2017
    Date of Patent: October 29, 2019
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Masami Yamada, Shinkichi Suzuki, Takahiro Sugimoto, Minoru Nakamura, Hiroki Sakamoto, Makoto Kamata
  • Heterocyclic compound
    Patent number: 10428056
    Abstract: The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity, which may be useful as a prophylactic or therapeutic drug for Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies and the like. The present invention relates to a compound represented by the formula (I) or a salt thereof: wherein each symbol is as defined in the attached DESCRIPTION.
    Type: Grant
    Filed: August 27, 2018
    Date of Patent: October 1, 2019
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Takahiro Sugimoto, Shinkichi Suzuki, Hiroki Sakamoto, Masami Yamada, Minoru Nakamura, Makoto Kamata, Kenichiro Shimokawa, Masataka Murakami, Jinichi Yonemori, Takuto Kojima